Benitec Corp (BNTC) - Earnings per share increase in current year
The annual EPS change step shown on this GURU.Markets chart, where the parameter value equals -24.00, highlights a lack of scalability and a cash flow deficit driven by R&D expenses. Benitec Biopharma Inc. (BNTC) automates DNA interference via AI and robotics to eliminate routine tasks. Their unique "gene silencing" method enables the one-time blocking of pathogenic proteins to cure hereditary pathologies.
Analytical breakdowns and data insights for company Benitec Biopharma Inc. (BNTC)
- price and consensus price forecast:
- market capitalization indicators:
- business book valuation details:
- debt burden and liquidity indicators:
Debt to Capital Benitec Biopharma Inc.|BNTC - Long-Term Debt to Equity|Current Liabilities to Equity Benitec Biopharma|BNTC - Company Aggregate Debts|Debt to Net Assets Ratio Benitec Biopharma|BNTC - Company Long-Term Debts|Company Short-Term Debts Benitec Biopharma|Intermediate Coverage Ratio benitec.com
- earnings and valuation multiples information:
BNTC - Company Net Income|Future Profit Benitec Biopharma Inc.|BNTC - P/E Multiple|Forward P/E Multiple Benitec Biopharma|BNTC - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Benitec Biopharma|BNTC - Operating profit EBITDA|Net earnings per share for the last four quarters Benitec Biopharma|BNTC - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months benitec.com|BNTC - Earnings growth in current year|Expected earnings per share growth for next year Benitec Biopharma Inc.
- sales volume and revenue information:
Fundamental valuation:Benitec (BNTC)
This indicator captures the year-over-year dynamics of earnings per share, reflecting the rate of change in the business's fundamental value to calculate a potential acquisition premium. By analyzing the annual EPS growth profile, an investor can see the lack of operating leverage at Benitec Biopharma Inc. (BNTC), where high R&D expenses and the clinical trial stage create a planned cash deficit.
Direct competitors
Tempus AI, Inc (TEM) - Earnings growth in current year|Earnings per share growth in current year Qiagen|IONS: Earnings per share increase in current year|Net earnings per share growth this year RGEN (Repligen)|Expected net earnings per share growth this year Avidity Biosciences Inc|Earnings growth in current year CRSP (crisprtx.com)|WGS: Earnings per share growth this year|RARE: Net earnings per share growth this year|Earnings per share trend in current year BEAM|Sarepta (SRPT) - Earnings per share growth in current year|TWST - Expected net earnings per share growth this year|Earnings per share growth in current year 10x Genomics, Inc.|NTLA: Earnings per share increase in current year|Net earnings per share growth this year STOK (Stoke Corp)|Expected net earnings per share growth this year biolifesolutions.com|Earnings growth in current year WVE (Wave Life Sciences Ltd)|Expected net earnings per share growth this year Maze Therapeutics (MAZE)|SION: Net earnings per share growth this year|Expected net earnings per share growth this year Prime Medicine Bio PRME|TSHA: Earnings growth in current year|Earnings per share growth this year QURE|Net earnings per share growth this year MGTX|Earnings per share growth this year RGNX (REGENXBIO)|Earnings growth in current year SLDB|OCGN - Earnings per share growth rate in current year|Earnings per share growth in current year Pacific Biosciences of California PACB|DSGN: Earnings per share growth this year|RCKT - Earnings per share growth in current year|4dmoleculartherapeutics.com (FDMT) - Net earnings per share growth this year|lexeotx.com (LXEO) - Earnings per share growth in current year|Korro Bio, Inc (KRRO) - Earnings growth in current year|EDIT (editasmedicine.com) - Earnings growth in current year|Earnings per share growth this year SLN (silence-therapeutics.com)|Earnings per share growth in current year proqr.com (PRQR)|Codexis - Earnings per share growth this year|Earnings growth in current year SGMO (Sangamo Therapeutics)|Earnings growth in current year nautilus.bio NAUT|Metagenomi Inc. - Earnings growth in current year|DTIL (Precision BioSciences Inc.) - Earnings per share growth this year|GBIO: Earnings growth in current year|Earnings per share growth rate in current year Boundless Bio, Inc (BOLD)|XCUR (Exicure) - Earnings growth in current year|Net earnings per share growth this year Imunon (IMNN)|Earnings growth in current year PHIO|Mustang Bio - Earnings per share growth this year|TransCode Therapeutics, Inc. - Net earnings per share growth this year|Expected net earnings per share growth this year Bionano Genomics, Inc. (BNGO)|APDN - Earnings per share growth in current year|Earnings per share increase in current year BLUE (Bluebird Bio)|ImmunoPrecise (IPA) - Earnings per share growth in current year|OMGA: Net earnings per one share growth for the current year|Earnings per share growth in current year Singular Genomics Systems, Inc.|Earnings growth in current year Regulus Therapeutics, Inc.|Net earnings per share growth this year SYRS (Syros)|TBIO - Earnings per share growth rate in current year|Earnings per share growth in current year TRACON Pharmaceuticals, Inc. TCON|Unity Biotechnology (UBX) - Earnings per share growth rate in current year
